CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma.

Rebecca Lee,Dominic G. Rothwell,Shien Chow,Heather Shaw,Samra Turajlic,N. J. T. Smith,Alexandra Clipson,Harry S. Clarke,Noel Kelso,Jackie Mitchell,Chris J Sutton,Gema Sylvestre,Paul Nathan,James Larkin,Philippa Corrie,Elizabeth Ruth Plummer,Richard Marais,Caroline Dive,Paul Lorigan

CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma.

2021

Rebecca Lee
Dominic G. Rothwell
Shien Chow
Heather Shaw
Samra Turajlic
N. J. T. Smith
Alexandra Clipson
Harry S. Clarke
Noel Kelso
Jackie Mitchell
Chris J Sutton
Gema Sylvestre
Paul Nathan
James Larkin
Philippa Corrie
Elizabeth Ruth Plummer
Richard Marais
Caroline Dive
Paul Lorigan

TPS9587Background: Circulating tumor DNA (ctDNA; the tumour derived fraction of circulating free DNA in the blood) has been shown to be a biomarker of tumor burden/progression in many cancers. We r...

Keywords:

Targeted therapy
Circulating free DNA
Medicine
cutaneous melanoma
Biomarker (medicine)
in patient
immune therapy
Cancer research
tumor burden
Circulating tumor DNA

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations